Source: Cytori Therapeutics
Date: January 30, 2008
Summary:
In an official company news release, Cytori Therapeutics, a biotechnology company in the field of adult stem cell research, announced the the treatment of the first patients participating in its clinical trial using Adult adipose (fat) stem and regenerative cells to treat heart attacks:
" Cytori Therapeutics (NASDAQ: CYTX) enrolled the first two patients in a clinical trial using adipose-derived stem and regenerative cells in the treatment of heart attack. In this trial, patients' cells are made available using Cytori's Celution™ System, a real-time cell processing device. One patient has been enrolled in each trial center, Hospital Universitario Gregorio Marañón in Madrid, Spain, and Thoraxcenter, Erasmus Medical Center in Rotterdam, The Netherlands."
